Cancer despite immunosurveillance: immunoselection and immunosubversion
The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Abstract
Numerous innate and adaptive immune effector cells and molecules participate in the recognition and destruction of cancer cells, a process that is known as cancer immunosurveillance. But cancer cells avoid such immunosurveillance through the outgrowth of poorly immunogenic tumour-cell variants (immunoselection) and through subversion of the immune system (immunosubversion). At the early stages of carcinogenesis, cell-intrinsic barriers to tumour development seem to be associated with stimulation of an active antitumour immune response, whereas overt tumour development seems to correlate with changes in the immunogenic properties of tumour cells. The permanent success of treatments for cancer might depend on using immunogenic chemotherapy to re-establish antitumour immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cancers must escape from immunosurveillance to advance to a clinically detectable state, meaning that they either are passively selected to ''hide'' from immune recognition (immunoselection) or actively suppress immune effectors (immunosubversion).249”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [249]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 1×
“By contrast, it is thought that TGFβ can also have immunostimulatory effects (in particular, on specific T H -cell subset”
BackgroundCuriel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The Pathophysiology of Mitochondrial Cell Death
Green, D. R., & Kroemer, G. (2004) · Science · doi:10.1126/science.1099320 · Cited by 3,418
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“More importantly, tryptophan degradation by indoleamine 2,3-dioxygenase ( IDO ), which is constitutively expressed by human tumours (particularly by prostate, colon and pancreatic carcinomas, but also by interdigitating DCs), promotes resistance to immune-mediated rejection of the tumour cell”
BackgroundImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Cited by
Items 401–500 of 1,000
Etokebe, G. E., Knežević, J., Petričević, B., Pavelić, J., Vrbanec, D., & Dembić, Z. (2009) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2009.0045 · Cited by 57
“In the immunosurveillance hypothesis, the immune system is regarded as a guardian of tissues protecting their integrity from undesired mutant cells (Zitvogel et al., 2006).”
The immunosuppressive tumor microenvironment in hepatocellular carcinoma
Pang, Y., Zhang, H., Peng, J., Pang, X., Yu, S., Xing, Q. R., Yu, X., Gong, L., Yin, Y., Zhang, Y. X., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0603-5 · Cited by 54
“By direct cytotoxicity or cytokine secretion, CD8 CTLs, IFN- producing CD4 T cells, NK cells, NKT cells, and T cells play an important role in anti-tumor immunity [51].”
BackgroundThe 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis—From Conception to Treatment
Weichselbaum, R. R. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00847 · Cited by 55
Yahata, T., Mizoguchi, M., Kimura, A., Orimo, T., Toujima, S., Kuninaka, Y., Nosaka, M., Ishida, Y., Sasaki, I., Fukuda‐Ohta, Y., et al. (2019) · Cancer Science · doi:10.1111/cas.13958 · Cited by 57
The Innate Immune Signalling Pathways: Turning RIG-I Sensor Activation against Cancer
Iurescia, S., Fioretti, D., & Rinaldi, M. (2020) · Cancers · doi:10.3390/cancers12113158 · Cited by 60
“Neoplastic cells develop various strategies to evade the host immunosurveillance [6,7].”
BackgroundDendritic cells and innate defense against tumor cells
Ullrich, E., Menard, C., Flament, C., Terme, M., Mignot, G., Bonmort, M., Plumas, J., Chaperot, L., Chaput, N., & Zitvogel, L. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.10.009 · Cited by 57
Assessment of the humoral immune response to cancer
Murphy, M., O’Leary, J. J., & Cahill, D. J. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.01.021 · Cited by 59
“An increased number of MSCs then act upon tumour specific T-cells, inhibiting the T-cell responses through nitric–oxide (NO) synthesis [5].”
BackgroundInfluentialOgawa, K., Hara, T., Shimizu, M., Nagano, J., Ohno, T., Hoshi, M., Ito, H., Tsurumi, H., Saito, K., Seishima, M., et al. (2012) · Oncology Letters · doi:10.3892/ol.2012.761 · Cited by 54
“Numerous immune effector cells and molecules recognize and destroy preneoplastic cells (1).”
Cui, P., Li, R., Huang, Z., Wu, Z., Tao, H., Zhang, S., & Hu, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-70207-7 · Cited by 51
Gauthier, M., Laroye, C., Bensoussan, D., Boura, C., & Decot, V. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103261 · Cited by 56
Schiarea, S., Solinas, G., Allavena, P., Scigliuolo, G. M., Bagnati, R., Fanelli, R., & Chiabrando, C. (2010) · Journal of Proteome Research · doi:10.1021/pr1001109 · Cited by 55
Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy
Buqué, A., Bloy, N., Aranda, F., Cremer, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., Tartour, É., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1149674 · Cited by 51
“, within the tumor microenvironment).(16,19-23) Extensive tumor infiltration by immunosuppressive cells (and/”
BackgroundVictories and deceptions in tumor immunology
Kroemer, G., Zitvogel, L., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23687 · Cited by 54
“Indeed, the progression of neoplastic lesions until an advanced (metastatic) stage is believed to require the subversion of natural anticancer immune responses, either as malignant cells actively inhibit immune effectors or upon the generation of escape variants that are not recognized by the immune system or are resi…”
BackgroundLlitjos, J., Auffray, C., Alby‐Laurent, F., Rousseau, C., Merdji, H., Bonilla, N., Toubiana, J., Belaïdouni, N., Mira, J. P., Lucas, B., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4744 · Cited by 56
“Numerous lines of evidence point to the major role of the immune system in the control of all stages of tumour development, from cell transformation to systemic dissemination [8].”
BackgroundBosi, A., Zanellato, S., Bassani, B., Albini, A., Musco, A., Cattoni, M., Desio, M., Nardecchia, E., D’Urso, D. G., Imperatori, A. S., et al. (2018) · Journal of Immunology Research · doi:10.1155/2018/2438598 · Cited by 52
“The concept of “escape from immune surveillance” by which the immune system could be subverted in the context of the tumor microenvironment [42] is the result of the balance between intratumor cytotoxic immune cells and immunosuppressive cells that can be used to predict the outcome of various cancers, such as early-s…”
Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source
Ruiu, R., Tarone, L., Rolih, V., Barutello, G., Bolli, E., Riccardo, F., Cavallo, F., & Conti, L. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.03.008 · Cited by 53
Tumor-intrinsic determinants of immunogenic cell death modalities
Workenhe, S. T., Pol, J. G., & Kroemer, G. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1893466 · Cited by 53
“In parallel, cancer cells must acquire the ability to prevent immune cell recognition and elimination.(40) The composition and function of immune cells in tumors vary greatly between and within cancer histotypes.”
BackgroundCheung, A. F., DuPage, M. J. P., Dong, H. K., Chen, J., & Jacks, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2634 · Cited by 49
“There are many mechanisms by which SIY-reactive T cells may be suppressed in K-ras;R26 mice (2, 38).”
BackgroundRoles of RNA-binding proteins in immune diseases and cancer
Hashimoto, S., & Kishimoto, T. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.017 · Cited by 53
Sarkar, A., Novohradský, V., Maji, M., Babu, T., Marková, L., Kostrhunová, H., Kašpárková, J., Gandin, V., Brabec, V., & Gibson, D. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202310774 · Cited by 50
Shen, W., Stone, K. D., Jales, A., Leitenberg, D., & Ladisch, S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4425 · Cited by 51
“However, tumors appear to possess several mechanisms to limit immune responses (44).”
BackgroundDrake, C. G., Sharma, P., & Gerritsen, W. R. (2013) · Oncogene · doi:10.1038/onc.2013.497 · Cited by 55
A Combined Chemoimmunotherapy Approach Using a Plasmid−Doxorubicin Complex
Bagalkot, V., Lee, I., Yu, M. K., Lee, E., Park, S., Lee, J.-H., & Jon, S. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800177f · Cited by 50
Immunologic Approaches to Ovarian Cancer Treatment
Sabbatini, P. J., & Odunsi, K. O. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0775 · Cited by 53
Emerging Roles of Long non-coding RNAs in The Tumor Microenvironment
Zhou, L., Zhu, Y., Sun, D., & Zhang, Q. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.44420 · Cited by 55
“Different types of infiltrated immune cells are important components of the TME and act together to help cancer cells to escape immune surveillance, thus generating a tumor-promoting microenvironment for proliferation and metastasis of cancer cells (22).”
BackgroundCharacterization of HLA class I altered phenotypes in a panel of human melanoma cell lines
Méndez, R., Rodríguez, T., Campo, A. D., Monge, E., Maleno, I., Aptsiauri, N., Jiménez, P., Pedrinaci, S., Pawelec, G., Ruiz‐Cabello, F., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0411-3 · Cited by 49
“Tumor cells have developed strategies to inhibit the expression and/or function of HLA class I antigens in order to escape CD8+ T-cell recognition and destruction [8, 14, 44].”
BackgroundDolen, Y., & Esendagli, G. (2013) · European Journal of Immunology · doi:10.1002/eji.201242814 · Cited by 48
Bonavida, B. (2014) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2014011929 · Cited by 51
“Tumor cells are inherently resistant to TRAIL apoptosis or selected for resistance by immune selection.(88) Resistance to apoptosis can be mediated by inhibitory proteins such as the Bcl-2 family of anti-apoptotic proteins(89) cFLIP short,(90) and inhibitors of apoptosis(91) all of which are targets of constitutively…”
BackgroundInvolvement of the Leptin Receptor in the Immune Response in Intestinal Cancer
Aloulou, N., Bastuji‐Garin, S., Gouvello, S. L., Abolhassani, M., Chaumette, M. T., Charachon, A., Leroy, K., & Sobhani, I. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0909 · Cited by 51
“The immunosurveillance system for tumor growth has been reported in several carcinomas (36) and involves inflammatory cells and lymphocytes, with regulatory T lymphocytes (LyTreg) and cytotoxic T cells being predictive of ineffective and effective antitumoral effects, respectively (37).”
BackgroundEsophageal cancer‐derived microvesicles induce regulatory B cells
Li, Y., An, J., Huang, S., He, J., & Zhang, J. (2015) · Cell Biochemistry and Function · doi:10.1002/cbf.3115 · Cited by 48
“It is suggested that cancer-immune tolerance is one of the factors to support cancer cells to escape from the immune surveillance to grow into tumours.(1) However, factors inducing cancer-immune tolerance have not been fully understood yet.”
BackgroundLanterna, C., Musumeci, A., Raccosta, L., Corna, G., Moresco, M. A., Maggioni, D., Fontana, R., Doglioni, C., Bordignon, C., Traversari, C., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1884-8 · Cited by 51
Klose, R., Krzywińska, E., Castells, M., Gotthardt, D., Putz, E. M., Kantari‐Mimoun, C., Chikdene, N., Meinecke, A., Schrödter, K., Helfrich, I., et al. (2016) · Nature Communications · doi:10.1038/ncomms12528 · Cited by 51
Kim, H., Griffith, T. S., & Panyam, J. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.254953 · Cited by 52
“IL-10 can promote tumor growth by directly inhibiting the function of effector T cells andNK cells, and by inducing the activation of immunosuppressive cells, including MDSCs, regulatory T cells (Tregs), and M2 macrophages (Zou, 2005; Zitvogel et al., 2006).”
BackgroundRamasubramanian, R., Meier, H. C. S., Vivek, S., Klopack, E. T., Crimmins, E. M., Faul, J. D., Nikolich‐Žugich, J., & Thyagarajan, B. (2022) · Immunity & Ageing · doi:10.1186/s12979-022-00290-z · Cited by 50
“The concept of immunosurveillance in cancer indicates that the immune system can recognize and proactively remove precursors of cancer and naïve T cells may be involved in this process as they perform immunosurveillance roles to undergo proliferation in response to homeostatic signals [43, 44].”
BackgroundYamamoto, K., Seike, M., Takeuchi, S., Soeno, C., Miyanaga, A., Noro, R., Minegishi, Y., Kubota, K., & Gemma, A. (2014) · Oncology Reports · doi:10.3892/or.2014.3481 · Cited by 51
“Tumors employ several mechanisms to avoid or actively suppress anticancer immune responses (9).”
BackgroundGenomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer
Coulouarn, C., Factor, V. M., Conner, E. A., & Thorgeirsson, S. S. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr133 · Cited by 47
Immune approaches to the treatment of breast cancer, around the corner?
Criscitiello, C., Espósito, A., Gelao, L., Fumagalli, L. A. M., Locatelli, M., Minchella, I., Adamoli, L., Goldhirsch, A., & Curigliano, G. (2014) · Breast Cancer Research · doi:10.1186/bcr3620 · Cited by 57
“Over the past few decades, a growing body of evidence has emerged demonstrating that the immune system participates both in tumor development (via chronic inflammation orchestrated by the innate immune system) and in tumor elimination and control (through the actions of the adaptive immune system) [4].”
BackgroundDominguez, C., Tsang, K.-Y., & Palena, C. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.297 · Cited by 47
Tamarov, K. P., Näkki, S., Xu, W., & Lehto, V. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb00462e · Cited by 54
Monitoring NK cell activity in patients with hematological malignancies
Viel, S., Charrier, E., Marçais, A., Rouzaire, P., Bienvenu, J., Karlin, L., Salles, G. A., & Walzer, T. (2013) · OncoImmunology · doi:10.4161/onci.26011 · Cited by 58
Spermidine reduces cancer-related mortality in humans
Pietrocola, F., Castoldi, F., Kepp, O., Carmona‐Gutiérrez, D., Madeo, F., & Kroemer, G. (2018) · Autophagy · doi:10.1080/15548627.2018.1539592 · Cited by 47
Martinet, L., Garrido, I., & Girard, J. (2012) · OncoImmunology · doi:10.4161/onci.19787 · Cited by 46
“Indeed, tumors often foster a tolerant microenvironment that counteracts effective antitumor immune responses.(5) In addition to these negative regulatory mechanisms, it appears that effector immune cells homing to tumors represent a major barrier to the efficiency of anti-tumor immune responses.”
Antigen Localization Controls T Cell-Mediated Tumor Immunity
Zeelenberg, I. S., van Maren, W. W. C., Boissonnas, A., Hout-Kuijer, M. A. V., den Brok, M. H., Wagenaars, J. A. L., van der Schaaf, A., Jansen, E. J. R., Amigorena, S., Théry, C., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003905 · Cited by 53
“immune response is not always effective and sometimes results in tolerance (1).”
BackgroundThe Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation
Musella, M., Galassi, C., Manduca, N., & Sistigu, A. (2021) · Biology · doi:10.3390/biology10090856 · Cited by 55
“Along with this, Type I IFNs contribute to the generation of an immunosuppressive TME taking part to a process known as immunosubversion, during which cancer cells skew immune cells toward dysfunctional or immunosuppressive phenotypes [218].”
BackgroundHua, L., Yang, Z., Li, W., Zhang, Q., Ren, Z., Ye, C., Zheng, X. W., Li, D., Long, Q., Bai, H., et al. (2021) · Advanced Materials · doi:10.1002/adma.202103923 · Cited by 48
Autophagy-targeted nanoparticles for effective cancer treatment: advances and outlook
Long, X., Yan, J., Zhang, Z., Chang, J., He, B., Sun, Y., & Liang, Y. (2022) · NPG Asia Materials · doi:10.1038/s41427-022-00422-3 · Cited by 50
Arum, C., Anderssen, E., Viset, T., Kodama, Y., Lundgren, S., Chen, D., & Zhao, C. (2010) · Neoplasia · doi:10.1593/neo.91824 · Cited by 45
“that effectively prevents tumor eradication by the host immune system, called “cancer immunoediting” [3,4].”
BackgroundLow recurrence of preexisting extrahepatic malignancies after liver transplantation
Benten, D., Sterneck, M. R., Panse, J., Rogiers, X., & Lohse, A. W. (2008) · Liver Transplantation · doi:10.1002/lt.21434 · Cited by 45
“Surveillance and elimination of tumor cells through various mechanisms represent an important challenge for the immune system, which can be impeded by immunosuppressive therapy in multiple ways, including attenuation of cytotoxic T-cell and natural killer cell functions and disturbance of humoral interaction with macr…”
BackgroundAntigen Processing and MHC-II Presentation by Dermal and Tumor-Infiltrating Dendritic Cells
Gerner, M. Y., & Mescher, M. F. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803479 · Cited by 58
Öhman, J. N., Mowjood, R., Larsson, L., Kovács, A., Magnusson, B., Kjeller, G., Jontell, M., & Hasséus, B. (2015) · PubMed · Cited by 56
Dendritic Cell Tumor Killing Activity and Its Potential Applications in Cancer Immunotherapy
Hanke, N. T., Alizadeh, D., Katsanis, E., & Larmonier, N. (2013) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2013006679 · Cited by 48
Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
Zamarin, D., & Wolchok, J. D. (2014) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2014.4 · Cited by 47
Tumorigenesis and anti-tumor immune responses in Xenopus
Goyos, A. (2009) · Frontiers in bioscience · doi:10.2741/3238 · Cited by 44
“Cancer immunosurveillance predicts that the immune system can recognize precursors of cancer and, in most cases, destroy these precursors before they become full blown cancer (55).”
BackgroundMocellin, S., & Nitti, D. (2007) · Medicinal Research Reviews · doi:10.1002/med.20110 · Cited by 47
Fucikova, J. P., Podrazil, M., Jarolím, L., Bílková, P., Hensler, M., Becht, É., Gašová, Z., Kloučková, J., Kayserová, J., Horváth, R., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2068-x · Cited by 44
Babikr, F., Wan, J., Xu, A., Wu, Z., Ahmed, S., Freywald, A., Chibbar, R., Wu, Y., Moser, M., Groot, G., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00796-4 · Cited by 49
“We measured the concentrations of three major cytokines including two representative immunogenic cytokines, IL-2 and IFN-γ, and one representative immunosuppressive cytokine, TGF-β, in mouse sera.”
BackgroundInfluentialAvogadri, F., Mittal, D., Saccheri, F., Fiore, M. S., Ciocca, M., Larghi, P., Orecchia, R., & Rescigno, M. (2008) · European Journal of Immunology · doi:10.1002/eji.200738035 · Cited by 46
Three are better than one: plasminogen receptors as cancer theranostic targets
Ceruti, P., Principe, M., Capello, M., Cappello, P., & Novelli, F. (2013) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-2-12 · Cited by 44
“Activation of the immune system is an early event during tumorigenesis, as illustrated by the detection of high titers of autoantibodies in patients with early-stage cancer, and correlates with the progression of malignant transformation [119,195,196].”
BackgroundTetraspanins in the immune response against cancer
Veenbergen, S., & van Spriel, A. B. (2011) · Immunology Letters · doi:10.1016/j.imlet.2011.03.010 · Cited by 45
“, variable expression of tumor antigens, ack of co-stimulatory molecules, and secretion of immunouppressive cytokines) facilitate tumor escape from immune estruction [24,25].”
BackgroundSpurny, C., Kailayangiri, S., Altvater, B., Jamitzky, S., Hartmann, W., Wardelmann, E., Ranft, A., Dirksen, U., Amler, S., Hardes, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23815 · Cited by 48
“com/oncotarget explanation is the presence of immune-inhibitory ligands and soluble agents in the microenvironment of solid tumors that tolerize T cells and render them dysfunctional against tumor targets (reviewed in [13, 14]).”
BackgroundThe role of cytokines in the evolution of cancer: IFN-γ paradigm
Todorović‐Raković, N. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155442 · Cited by 49
Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients
Beneduce, L., Prayer‐Galetti, T., Giustinian, A. M. G., Gallotta, A., Betto, G., Pagano, F. C., & Fassina, G. (2007) · Cancer Detection and Prevention · doi:10.1016/j.cdp.2007.10.005 · Cited by 42
“The cancer immunosurveillance predicts that the immune system can recognize the precursors of cancer (immunoediting) by native or adaptive immune effectors and, in most cases, can destroy the cancer cells before they become clinically apparent [19,20].”
BackgroundCytokine adsorption/release on uniform magnetic nanoparticles for localized drug delivery
Mejías, R., Costo, R., Roca, A. G., Fernández-Arias, C., Veintemillas-Verdaguer, S., González-Carreño, T., Morales, M. P., Serna, C. J., Mañes, S., & Barber, D. F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.028 · Cited by 42
“There is considerable recent pre-clinical and clinical evidence showing that manipulation of the innate and adaptive immune responses to neoplastic cells can control development of tumors, leading to their elimination [3–5].”
Targeting immune checkpoints: New opportunity for mesothelioma treatment?
Marcq, E., Pauwels, P., van Meerbeeck, J. P., & Smits, E. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.09.006 · Cited by 48
Vassallo, J., Rodrigues, A. F. F., Campos, A. H. J. F. M., Rocha, R. M., da Cunha, I. W., Zéqui, S. D. C., Guimarães, G. C., da Fonseca, F. P., Lopes, A., Cubilla, A. L., et al. (2015) · Tumor Biology · doi:10.1007/s13277-014-2864-2 · Cited by 40
“There is mounting evidence that immune cells trigger diverse mechanisms that enhance growth and metastasis in a variety of tumors, especially those involving regulatory T lymphoid cells [7, 8].”
BackgroundTumor stroma and chemokines control T-cell migration into melanoma following Temozolomide treatment
Tan, K. W., Evrard, M., Tham, M., Hong, M. L. W., Huang, C. W., Kato, M., Prévost‐Blondel, A., Donnadieu, E., Ng, L. G., & Abastado, J. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.978709 · Cited by 46
“There are several possible explanations for this apparent paradox - a lack of specificity of the T cells, immune suppression within the tumor local environment and/or insufficient recruitment of T cells to the tumor site.(6,7) The present study investigates this last factor.”
BackgroundGaitanis, G., Velegraki, A., Magiatis, P., Pappas, P., & Bassukas, I. D. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.03.020 · Cited by 45
“Regarding the pathogenesis of BCC recent data mainly implicate activating mutations of the hedgehog pathway at the cellular level [21–23] as well as induction of immune tolerance locally by the establishing tumor [24,25] at the tissue level [26] (immunosubversion), a well recognized common process in the progression o…”
BackgroundOgawa, K., Hara, T., Shimizu, M., Ninomiya, S., Nagano, J., Sakai, H., Hoshi, M., Ito, H., Tsurumi, H., Saito, K., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02237.x · Cited by 43
Kokowski, K., Stangl, S., Seier, S., Hildebrandt, M., Vaupel, P. W., & Multhoff, G. (2019) · Strahlentherapie und Onkologie · doi:10.1007/s00066-019-01434-9 · Cited by 41
Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours
White, L. G., Goy, H. E., Rose, A. J., & McLellan, A. D. (2022) · Cancers · doi:10.3390/cancers14040978 · Cited by 43
“Immune tolerance or ignorance of tumour cell masses may relate to it being a property of malignant cell masses that they closely resemble undifferentiated, immune-privileged tissues, as well as ongoing Darwinian cell selection to immune-evasive phenotypes [19].”
BackgroundSiew, Y.-Y., Neo, S.-Y., Yew, H.-C., Lim, S.-W., Ng, Y.-C., Lew, S.-M., Seetoh, W.-G., Seow, S.-V., & Koh, H. (2015) · International Immunology · doi:10.1093/intimm/dxv041 · Cited by 45
Cross-reactivity between microbial and tumor antigens
Zitvogel, L., & Kroemer, G. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102171 · Cited by 40
Self-citationKaarvatn, M. H., Vrbanec, J., Kulić, A., Knežević, J., Petričević, B., Balen, S., Vrbanec, D., & Dembić, Z. (2012) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2012.02736.x · Cited by 41
Immunotherapy in acute myeloid leukemia
Grosso, D. A., Hess, R., & Weiss, M. A. (2015) · Cancer · doi:10.1002/cncr.29378 · Cited by 45
Prognostic biomarkers in ovarian cancer
Huang, J., Hu, W., & Sood, A. K. (2011) · Cancer Biomarkers · doi:10.3233/cbm-2011-0212 · Cited by 53
“Given the well-established importance of the immune system in tumor development [217,218], researchers are striving to find novel immune-related prognostic biomarkers.”
BackgroundControl of the Adaptive Immune Response by Tumor Vasculature
Mauge, L., Terme, M., Tartour, É., & Helley, D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00061 · Cited by 49
Chang, C., Lo, C., Shih, Y., Chen, Y. M., Wu, P., Tsuneyama, K., Roffler, S. R., & Tao, M. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.187 · Cited by 40
“…there is an urgent need to develop more effective therapeutic strategies to treat HCC. CD8 þ T cells and natural killer (NK) cells play important roles in cancer immunosurveillance by directly killing malignant cells (Street et al. , 2004; Zitvogel et al. , 2006; Wald-hauer and Steinle, 2008).”
Maes, W., Verschuere, T., Hoylandt, A. V., Boon, L., & Gool, S. V. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/952469 · Cited by 46
“However, as malignancy progresses, few tumor cells escape the immunosurveillance, finally leading to clinically detectable tumors that are often very hard to cure [1].”
BackgroundTFAM is a novel mediator of immunogenic cancer cell death
Yang, M., Li, C., Zhu, S., Cao, L., Kroemer, G., Zeh, H. J., Tang, D., & Kang, R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1431086 · Cited by 43
“Several novel therapeutic approaches focus on rebuilding immune surveillance in the tumor microenvironment.(1)”
BackgroundThe Adaptive Complexity of Cancer
Derbal, Y. (2018) · BioMed Research International · doi:10.1155/2018/5837235 · Cited by 45
Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer
Ino, K. (2010) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e3283409c79 · Cited by 46
Chakrabarti, L., Abou-Antoun, T., Vukmanović, S., & Sandler, A. D. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00082 · Cited by 43
Del Campo, A. B., Aptsiauri, N., Méndez, R., Zinchenko, S., Vales, Á., Paschen, A., Ward, S., Ruiz‐Cabello, F., González‐Aseguinolaza, G., & Garrido, F. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02276.x · Cited by 40
Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma
Cai, M., Wang, Y., Ma, H., Li, Y., & Xu, Z. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102840 · Cited by 49
“For example, transforming growth factor β (TGF-β ) hampers antitumor immune responses by inhibiting CTLs and facilitating Tregs proliferation [43].”
Immunotherapy of Breast Cancer
Criscitiello, C., & Curigliano, G. (2015) · Progress in tumor research · doi:10.1159/000437183 · Cited by 45
Peng, T., Tsai, F., & Wu, T. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.05.019 · Cited by 39
Racial Differences in Immunological Landscape Modifiers Contributing to Disparity in Prostate Cancer
Thomas, J. K., Mir, H., Kapur, N., & Singh, S. (2019) · Cancers · doi:10.3390/cancers11121857 · Cited by 41
“During immuno-sculpting, selected cancer cells that are tolerant of immune attack, after exposure to the effector immune cells, steer the immune response by production of selective cytokines for recruitment of suppressive immune cells and facilitate proliferation after escaping elimination [53].”
BackgroundNLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer
Sonnessa, M., Cioffi, A., Brunetti, O., Silvestris, N., Zito, F. A., Saponaro, C., & Mangia, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01587 · Cited by 44
Contribution du système immunitaire à l’efficacité des chimiothérapies anticancéreuses
Zitvogel, L., Tesnière, A., Apétoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32694-9 · Cited by 53
Alshaker, H. A., Qinna, N. A., Qadan, F., Bustami, M., & Matalka, K. Z. (2011) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-11-9 · Cited by 41
“Unfortunately, cancer cells are capable of avoiding this process by immunoselection of poorly immunogenic tumor cells along with subversion of the immune system and thus shaping both the tumor and its microenvironment [1].”
BackgroundDong, Y., Yuan, Q., Ren, J., Li, H., Guo, H., Guan, H., Jiang, X., Qi, B., & Li, R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1090906 · Cited by 39
“Owing to the mounting evidence suggesting a pivotal function for immune cells and immune checkpoint genes (ICGs) in tumorigenesis (21, 22), We probed whether the oxidative metabolism score was linked to ICI and ICGs.”
CD8α+ DC are not the sole subset cross‐presenting cell‐associated tumor antigens from a solid tumor
McDonnell, A. M., Prosser, A., van Bruggen, I., Robinson, B. W. S., & Currie, A. J. (2010) · European Journal of Immunology · doi:10.1002/eji.200940153 · Cited by 42
Schirrmacher, V., Fournier, P., & Schlag, P. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2014.854169 · Cited by 39
Khandelwal, N., Breinig, M., Speck, T., Michels, T., Kreutzer, C., Sorrentino, A., Sharma, A. K., Umansky, L., Conrad, H., Poschke, I. C., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404414 · Cited by 39
“However, tumor cells use immune checkpoints to prevent immune recognition (Zitvogel et al, 2006; Rabinovich et al, 2007).”
Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
del Bano, J., Chames, P., Baty, D., & Kerfélec, B. (2015) · Antibodies · doi:10.3390/antib5010001 · Cited by 42
“The final phase describes the tumor escape from the immunological control through several mechanisms and the outgrowth of tumor [8–10,12,21–23].”
BackgroundZhang, Y., Cao, Y. Q., Sun, X., Feng, Y., Du, Y., Liu, F., Yu, C., & Jin, F. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.11.027 · Cited by 39
Immunotherapy for Pediatric Brain Tumors
Sayour, E. J., & Mitchell, D. A. (2017) · Brain Sciences · doi:10.3390/brainsci7100137 · Cited by 38
“As malignancies gain mutations they evolve to resist the immune system, while actively subverting it from inducing anti-tumor activity [56,57].”
BackgroundRusso, L., Maltese, A., Betancourt, L., Romero, G., Cialoni, D., la Fuente, L. D., Gutierrez, M., Ruiz, A., Agüero, E., & Hernandez, S. F. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.01.222 · Cited by 38
Metformin Effects on FOXP3+ and CD8+ T Cell Infiltrates of Head and Neck Squamous Cell Carcinoma
Amin, D. R., Richa, T., Mollaee, M., Zhan, T., Tassone, P. T., Johnson, J. M., Luginbuhl, A., Cognetti, D. M., Martinez‐Outschoorn, U., Stapp, R., et al. (2019) · The Laryngoscope · doi:10.1002/lary.28336 · Cited by 42
Salem, M. L., El-Shanshory, M. R., Abdou, S., Attia, M. S., Sobhy, S. M., Zidan, M. F., & Zidan, A. A. (2018) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2018.1424897 · Cited by 38
Metadata
- Authors
- Zitvogel, L., Tesniere, A., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Kroemer, Guido
- Venue
- Nature reviews. Immunology
- Published
- 2006-09-15
- Volume
- 6
- Issue
- 10
- Pages
- 715-727
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2063192133
- Cited by
- 1,324
- References
- 127
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 62 · 2023: 75 · 2022: 68 · 2021: 63 · 2020: 63 · 2019: 60 · 2018: 66 · 2017: 76 · 2016: 72 · 2015: 81 · 2014: 87 · 2013: 89 · 2012: 82
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission
- Conseil Régional, Île-de-France
- Institut National Du Cancer
- Cancéropôle Ile de France
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor surveillance, immunoselection, tumor immunogenicity, antitumor immunity, carcinogenesis, immunogenic chemotherapy
- MeSH terms
- Animals, Humans, Immune Tolerance, Immunologic Surveillance, Neoplasms, T-Lymphocytes, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.